🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Non-small Cell Lung Cancer (NSCLC)

Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Trilaciclib combined with Docetaxel VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer NCT07026110NA1 site📍 Shanghai RenJi Hospital · Tests: [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4, [18F]F-RESCA-RT4, [18F]F-RESCA-EPCD6 Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance NCT07483983Phase 27 sites📍 Villejuif📍 Bordeaux📍 Dijon Gustave Roussy, Cancer Campus, Grand Paris · Tests: ASP3082 A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) NCT05657873Phase 29 sites📍 Miami📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer NCT02133196Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer NCT06928389Phase 31 site📍 Shanghai Akeso · Tests: Ivonescimab, docetaxel, Placebo, docetaxel JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation NCT06416410Phase 337 sites📍 Hefei📍 Beijing📍 Beijing Allist Pharmaceuticals, Inc. · Tests: JAB-21822, Tislelizumab, JAB-3312, Pemetrexed, Carboplatin A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764Phase 274 sites📍 Washington D.C.📍 Athens📍 Lexington Bristol-Myers Squibb · Tests: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin RGL-270 + ICI in Advanced NSCLC NCT07652125NA1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: RGL-270 in Combination with PD-1/PD-L1 Inhibitors, Physician's Choice SOC Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade NCT07130032Phase 21 site📍 Saint Petersburg EuroCityClinic LLC · Tests: reICB regimen (NSCLC), reICB regimen (melanoma) A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) NCT06731907Phase 241 sites📍 Lexington📍 Baltimore📍 Fargo Merck Sharp & Dohme LLC · Tests: Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan NCT06358222n/a1 site📍 Shanghai Shanghai Chest Hospital · Tests: Blood ctDNA + methylation + PET-CT and Postoperative pathology, MRD+ methylation (or combined with PET-CT) and Invasive… A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation NCT07012031Phase 1, Phase 29 sites📍 Sacramento📍 Tampa📍 Tampa National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 NCT04613596Phase 2, Phase 3770 sites📍 Goodyear📍 Prescott Valley📍 Safford Mirati Therapeutics Inc. · Tests: Adagrasib, Adagrasib, Adagrasib, Adagrasib, Pembrolizumab Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer NCT06684418n/a1 site📍 Shanghai Fudan University · Tests: chest enhanced CT Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab NCT07510724n/a2 sites📍 Sankt Pölten📍 Frankfurt am Main Institut für Klinische Krebsforschung IKF GmbH at Krankenha… BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer NCT03199651NA1 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Best Practice, Biospecimen Collection, Biospecimen Collection, Laboratory Biomarker Analysis, Medical Chart Review A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors NCT07056556Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M09D1 A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer NCT07603856Phase 21 site📍 Chicago University of Chicago · Tests: Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Inve… A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer NCT06868277Phase 3304 sites📍 La Mesa📍 Los Alamitos📍 Newark AstraZeneca · Tests: Rilvegostomig, Pembrolizumab Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer NCT07288632n/a1 site📍 Perugia University Of Perugia Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients NCT06114108NA7 sites📍 Aarau📍 Bellinzona📍 Chur Swiss Cancer Institute · Tests: Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy), Surgery, Radiotherapy Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer NCT07436858Phase 11 site📍 Amsterdam The Netherlands Cancer Institute · Tests: PET imaging with ⁸⁹Zr-trastuzumab, Blood sampling for pharmacokinetics FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations NCT06669117Phase 1, Phase 219 sites📍 Washington D.C.📍 Canton📍 Nashville Pierre Fabre Medicament · Tests: VERT-002 A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites📍 Grand Rapids📍 St Louis📍 Pittsburgh AstraZeneca · Tests: AZD6750, rilvegostomig
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy